01-11-2017 06:27 PM CET - Health & Medicine

Hyper IgM Foundation Research Grants:

Press release from: Hyper IgM Foundation

FOR IMMEDIATE RELEASE: January 11 , 2017.

The Hyper IgM Foundation is proud to announce the availability of seed grant funding for researchers interested in the advancement of a cure for Hyper IgM Syndrome and primary immunodeficiency disorders. The intent of these grants is to accelerate scientific work focused on improving the treatment, quality of life, and long-term outlook for patients with Hyper IgM. Special consideration will be given to well-defined projects focused on gene therapy/editing for CD40 Ligand Deficiency as well as hematopoietic stem cell transplantation for CD40 Ligand Deficiency.

During the calendar years 2017 and 2018, the Hyper IgM Foundation will be awarding one-time grants of up to $5,000 to worthy recipients each year. The 2017 Grant recipients may be eligible for an additional one-time grant of up to $5,000 in 2018. Grant applications will be considered twice per year with submission deadlines of April 30th, 2017 and September 30th, 2017.

Complete and relevant proposals will be reviewed by the Hyper IgM Foundation’s Research Committee (RC), which may solicit feedback from members of the Hyper IgM Foundation’s Scientific Advisory Committee. Any conflicts of interest will be disclosed in the review minutes and will be reported on grant approvals.

Conditions of The Grant:

Funds may not be used for any combination of salary and/or lab support absent prior written approval from the Hyper IgM Foundation.

Recipient must make proper acknowledgements in presentations and publications resulting from the research sponsored by the grant. Recipient will also notify the Research Committee of any publications resulting from the work supported by the Hyper IgM Foundation grant.

The recipient must submit a final written progress report to the Hyper IgM Foundation at the conclusion of the award period. It is also expected that the grant recipient will present the final results of their research at a future Hyper IgM Foundation board meeting or teleconference.

Application Process:

Complete and return the Research Grant Application, with the following documents attached thereto:

Applicant’s Personal Statement:
- Not to exceed one page
- Summarize your training to date
- Comment on your specific clinical and research interests

Detailed Research Proposal:
- Outline the specific aims, background, methodology, purpose, and goals of the intended project
- Tables, figures, and graphs, etc. may also be included as supplemental documentation to support the proposal

Budget and Budget Justification:
- A budget and detailed budget justification must be attached with the application. The budget justification should not exceed 2 pages

- Include documentation, if applicable, that the proposed research was approved by the Institutional Animal Care and Use Committee (IACUC) or human subjects Institutional Review Board (IRB) of the grantee institution

Curriculum Vitae/Biosketch:
- Please attach your most current curriculum vitae or biosketch, highlighting experience as it relates to your proposed project. Please also list publications in order of relevance to the proposal
- Primary Mentor Biographical Sketch (NIH Format)

Application Submission and Inquiries:

The Hyper IgM Foundation accepts submissions of the Research Grant Application and all required materials by email at research@hyperigm.org.

Please try to submit all materials in one PDF.

All inquiries should be submitted to the Hyper IgM Foundation by contacting research@hyperigm.org.

Hyper IgM Foundation, a non-profit organization, was founded in 2015 by dedicated parents, healthcare professionals and friends. Our mission is to improve the treatment, quality of life and the long term outlook for children and adults living with Hyper IgM through research, support, education, and advocacy to families and patients.

Hyper IgM Foundation
215 W101st Street. Suite 7B
New York, NY 10025
United State of America

This release was published on openPR.
News-ID: 410776 • Views: 471
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: